Renin inhibitors
    2.
    发明公开
    Renin inhibitors 失效
    Renininhibitoren。

    公开(公告)号:EP0456185A2

    公开(公告)日:1991-11-13

    申请号:EP91107400.3

    申请日:1991-05-07

    摘要: A renin inhibiting compound of the formula:

    wherein R₁ is 4-piperazinyl, 1-methyl-4-piperazinyl, 1-methyl-1-oxo-4-piperazinyl, 2-oxo-4-piperazinyl, 4-morpholinyl, 4-thiomorpholinyl or 1-methyl-4-homopiperazinyl;
    R₂ is benzyl, 2-phenylethyl, 1-naphthylmethyl or 2-naphthylmethyl;
    R₃ is 4-thiazolyl, 2-amino-4-thiazolyl, 2-thiazolyl, 5-thiazolyl, 1-pyrazolyl, 3-pyrazolyl, 1-imidazolyl, n-propyl, isopropyl, CH₃S- or CH₃SCH₂-;
    R₄ is isobutyl or cyclopropyl;
    R₅ is hydrogen or loweralkyl; and
    X is CH₂ or NH; or a pharmaceutically acceptable salt, ester or prodrug thereof; with the proviso that when X is NH and R₃ is 2-amino-4-thiazolyl, then R₄ is cyclopropyl.

    摘要翻译: 其中R1是4-哌嗪基,1-甲基-4-哌嗪基,1-甲基-1-氧代-4-哌嗪基,2-氧代-4-哌嗪基,4-吗啉基,4-吗啉基, 4-硫代吗啉基或1-甲基-4-高哌嗪基; R2是苄基,2-苯基乙基,1-萘基甲基或2-萘基甲基; R 3是4-噻唑基,2-氨基-4-噻唑基,2-噻唑基,5-噻唑基,1-吡唑基,3-吡唑基,1-咪唑基,正丙基,异丙基,CH 3 S-或CH 3 SCH 2 - R4是异丁基或环丙基; R5是氢或低级烷基; X为CH 2或NH; 或其药学上可接受的盐,酯或前药; 条件是当X是NH且R 3是2-氨基-4-噻唑基时,则R 4是环丙基。

    Peptidyl difluorodiol renin inhibitors
    8.
    发明公开
    Peptidyl difluorodiol renin inhibitors 失效
    肽基二氟二醇肾素抑制剂

    公开(公告)号:EP0416393A1

    公开(公告)日:1991-03-13

    申请号:EP90116225.5

    申请日:1990-08-24

    摘要: A renin inhibiting compound of the formula:
    wherein A is a functional group;
    W is

    (1) -C(O)-,
    (2) -CH(OH)- or
    (3) -N(R₂)- wherein R₂ is hydrogen or loweralkyl;
    U is

    (1) -C(O)-,
    (2) -CH₂- or
    (3) -N(R₂)- wherein R₂ is hydrogen or lower alkyl, with the proviso that when W is -CH(OH)- then U is -CH₂- and with the proviso that U is -C(O)- or -CH₂- when W is -N(R₂)-;
    V is

    (1) -CH-,
    (2) -C(OH)- or
    (3) -C(halogen)- with the proviso that v is -CH-­when U is -N(R₂)-;
    Q is -CH(R₁)- or -C(=CHR 1a )- wherein R₁ is

    (1) loweralkyl,
    (2) cycloalkylalkyl,
    (3) arylalkyl,
    (4) (heterocyclic)alkyl,
    (5) 1-benzyloxyethyl,
    (6) phenoxy,
    (7) thiophenoxy or
    (8) anilino, provided that B is -CH₂- or -CH(OH)- or A is hydrogen when R₁ is phenoxy, thiophenoxy or anilino and R 1a is aryl or heterocyclic;
    R₃ is a functional group;
    R₄ is

    (1) loweralkyl,
    (2) cycloalkylmethyl or
    (3) benzyl;
    R₅ is -CH(OH)- or -C(O)-;
    R₆ is -CH(OH)- or -C(O)-; and
    Z is

    (1) lower alkyl,
    (2) aryl,
    (3) arylalkyl,
    (4) cycloalkyl,
    (5) cycloalkylalkyl,
    (6) heterocyclic or
    (7) (heterocyclic)alkyl;
    or a pharmaceutically acceptable salt, ester or prodrug thereof.

    摘要翻译: 下式的肾素抑制化合物:其中A是官能团; W是(1)-C(O) - ,(2)-CH(OH) - 或(3)-N(R 2) - ,其中R 2是氢或低级烷基; U是(1)-C(O) - ,(2)-CH 2 - 或(3)-N(R 2) - ,其中R 2是氢或低级烷基,条件是当W是-CH(OH) U是-CH 2 - ,并且条件是当W是-N(R 2) - 时,U是-C(O) - 或-CH 2 - ; 当U是-N(R 2) - 时,V是(1)-CH-,(2)-C(OH) - 或(3)-C(卤素) - ,条件是v是-CH-。 (1)低级烷基,(2)环烷基烷基,(3)芳基烷基,(4)(杂环)烷基,(5)1-苄氧基乙基,(苄基) 6)苯氧基,(7)苯硫基或(8)苯胺基,条件是当R 1为苯氧基时,B为-CH 2 - 或-CH(OH) - 或A为氢,硫代苯氧基或苯胺基,R 1a为芳基或杂环; R 3是一个官能团; (1)低级烷基,(2)环烷基甲基或(3)苄基; R 5是-CH(OH) - 或-C(O) - ; R 6是-CH(OH) - 或-C(O) - ; (1)低级烷基,(2)芳基,(3)芳基烷基,(4)环烷基,(5)环烷基烷基,(6)杂环或(7)(杂环) 或其药学上可接受的盐,酯或前药。